trending Market Intelligence /marketintelligence/en/news-insights/trending/ids2fqxldrftfw41z3vb9a2 content esgSubNav
In This List

InMed Pharmaceuticals secures conditional approval to list on TSX

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


InMed Pharmaceuticals secures conditional approval to list on TSX

InMed Pharmaceuticals Inc. said it received conditional approval to list its common shares on the Toronto Stock Exchange.

Final approval is subject to customary listing conditions which the company expects to meet before the May 29 deadline.

The Vancouver, British Columbia-based company's shares will continue to trade under the symbol IN.

Further, InMed plans to voluntarily delist its common shares from the Canadian Stock Exchange. The delisting will take effect on the date the company's shares begin trading on TSX.

InMed develops cannabinoid-based prescription drug therapies.